Flutter Entertainment has announced a major expansion of its partnership with Cure Leukaemia, becoming the charity’s first-ever global corporate partner under a three-year agreement running to 2028.
Building on Flutter’s long-standing support for the charity, the renewed and extended partnership significantly enhances the scale and global reach of its colleague fundraising and its impact. It is expected to generate $1.3 million (or £1 million) every year for Cure Leukaemia, supporting six major clinical trials already primed for delivery and allowing expansion of the globally significant Trials Acceleration Programme from 15 centres to 25. Flutter’s financial commitment will also secure funding of the complementary IMPACT networks – one of only two transplant and cell therapy trials networks in the world – and the recently established MyeCare Registry generating real world data on UK patients with acute myeloid leukaemia.
Since its inception in 2023, the partnership has already raised more than $2.7 million in new funding for the blood cancer-focused charity, driven by colleague participation in endurance events and headline sponsorship of the charity’s “The Tour 21” and “London2Paris” events. This substantial contribution has accelerated clinical trial timelines, strengthened specialist nurse provision and improved access to potentially life-saving treatments for people with blood cancers across the UK.
As a new global partner, Flutter will continue as headline supporter of these cycling initiatives, while expanding the partnership globally through the launch of the Cure Leukaemia Running Club. This evolution will offer Flutter’s 29,000 colleagues across more than 30 countries the opportunity to take part in flagship marathon and other running events, virtual challenges and community fundraising initiatives worldwide. The addition of running-focused initiatives will directly contribute to funding two clinical trials per year and support specialist clinical trials nurses in ten new centres.
Kerry McNally, Group Head of Communities and Engagement at Flutter Entertainment, said: “This partnership brings together two things that matter deeply to our people. The power of sport to bring communities together and the belief that everyone deserves access to better health outcomes. What makes this so powerful is that it is driven by our colleagues. Their energy, commitment, and willingness to push themselves to make a difference. Becoming Cure Leukaemia’s first global partner allows us to scale that collective effort and deliver real impact for patients around the world.”
James McLaughlin, Chief Executive of Cure Leukaemia, said: “Flutter’s support since 2023 has been of pivotal importance in funding pioneering clinical trials with the potential to transform the lives of blood cancer patients across the UK. What has been especially striking is the way colleagues from Flutter have consistently fronted up, with passion, energy, and commitment for our cause.
“Their collective effort has been instrumental to our impact so far, and this new global commitment will allow us to run more trials, expand the Trials Acceleration Program, and reach more families who urgently need access to the latest treatments. In December 2025, a number of globally impacting clinical trials were presented at the American Society of Haematology Conference, including the AMMO trial, which is supported through the Trials Acceleration Program, demonstrating the global impact and importance of Flutter’s continued support.”
